Duprey Lauren Rusckowski 4

What Happened Lauren Duprey Rusckowski, Chief Transformation Officer of Takeda Pharmaceutical Co. Ltd. (TAK), received an award of 45,140 restricted stock units (RSUs) on July 1, 2026. The grant was reported on a Form 4 filed July 6, 2026. The RSUs were granted at $0.00 per unit (no cash paid at grant); each RSU represents a contingent right to receive one American Depositary Share (ADS) upon vesting.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-06.
• Award: 45,140 RSUs; reported acquisition price: $0.00 (total $0 at grant).
• Vesting: RSUs vest in three equal annual installments beginning July 1, 2027 (per footnote).
• Shares owned after transaction: not specified in the filing.
• Filing notes: grant reported on the Form 4 dated July 6, 2026; no additional filing exceptions or 10b5-1/late-filing flags are indicated in the provided data.

Context RSU grants are a form of compensation — they do not deliver shares or cash immediately. Value to the holder depends on Takeda’s ADS market price when each tranche vests; taxes and any required withholding typically occur at vesting. Such awards are common for executives and are not, by themselves, explicit signals to buy or sell the stock.